Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Draft Guidance for Industry: Cooperative Manufacturing Arrangements for Licensed Biologics, 65034-65036 [E7-22489]
Download as PDF
<![CDATA[
65034
Federal Register / Vol. 72, No. 222 / Monday, November 19, 2007 / Notices
agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Recordkeeping and Records Access
Requirements for Food Facilities—21
CFR 1.337, 1.345, and 1.352 (OMB
Control Number 0910–0560)—Extension
The Public Health Security and
Bioterrorism Preparedness and
Response Act of 2002 (the Bioterrorism
Act) added section 414 of the Federal
Food, Drug, and Cosmetic Act (the act)
(21 U.S.C. 350c), which requires that
persons who manufacture, process,
pack, hold, receive, distribute, transport,
or import food in the United States
establish and maintain records
identifying the immediate previous
sources and immediate subsequent
recipients of food. Sections 1.326
through 1.363 (21 CFR 1.326 through
1.363) of FDA’s regulations set forth the
requirements for recordkeeping and
records access. The requirement to
establish and maintain records improves
FDA’s ability to respond to, and further
contain, threats of serious adverse
health consequences or death to humans
or animals from accidental or deliberate
contamination of food.
Description of Respondents: Persons
that manufacture, process, pack, hold,
receive, distribute, transport, or import
food in the United States are required to
establish and maintain records,
including persons that engage in both
interstate and intrastate commerce.
FDA’s regulations require that records
for non-transporters include the name
and full contact information of sources,
recipients, and transporters, an adequate
description of the food including the
quantity and packaging, and the receipt
and shipping dates (§§ 1.337 and 1.345).
Required records for transporters
include the names of consignor and
consignee, points of origin and
destination, date of shipment, number
of packages, description of freight, route
of movement and name of each carrier
participating in the transportation, and
transfer points through which shipment
moved (§ 1.352). Existing records may
be used if they contain all of the
required information and are retained
for the required time period.
FDA estimates the burden of this
collection of information as follows:
TABLE 1.—ESTIMATED ANNUAL RECORDKEEPING BURDEN 1
21 CFR Section
No. of
Recordkeepers
Annual Frequency
of Recordkeeping
Total Annual
Records
Hours per
Record
Total Hours
1.337, 1.345, and 1.352
(records maintenance)
379,493
1
379,493
13.228
5,020,000
1.337, 1.345, and 1.352
(learning for new firms)
18,975
1
18,975
4.790
90,890
Total
rwilkins on PROD1PC63 with NOTICES
1 There
5,110,890
are no capital costs or operating and maintenance costs associated with this collection of information.
This estimate is based on FDA’s
estimate of the number of facilities
affected by the final rule entitled
‘‘Establishment and Maintenance of
Records Under the Public Health
Security and Bioterrorism Preparedness
and Response Act of 2002,’’ published
in the Federal Register of December 9,
2004 (69 FR 71562 at 71630). With
regard to records maintenance, FDA
estimates that approximately 379,493
facilities will spend 13.228 hours
collecting, recording, and checking for
accuracy of the limited amount of
additional information required by the
regulations, for a total of 5,020,000
hours annually. In addition, FDA
estimates that new firms entering the
affected businesses will incur a burden
from learning the regulatory
requirements and understanding the
records required for compliance. In this
regard, the agency estimates the number
of new firms entering the affected
VerDate Aug<31>2005
20:17 Nov 16, 2007
Jkt 214001
businesses to be five percent (5%) of
379,493, or 18,975 firms. Thus, FDA
estimates that approximately 18,975
facilities will spend 4.790 hours
learning about the recordkeeping and
records access requirements, for a total
of 90,890 hours annually. Therefore, the
total annual recordkeeping burden is
estimated to be 5,110,890 hours.
Dated: November 13, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E7–22480 Filed 11–16–07; 8:45 am]
BILLING CODE 4160–01–S
PO 00000
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 1999D–2013]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Draft Guidance for
Industry: Cooperative Manufacturing
Arrangements for Licensed Biologics
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
Frm 00049
Fmt 4703
Sfmt 4703
E:\FR\FM\19NON1.SGM
19NON1
Federal Register / Vol. 72, No. 222 / Monday, November 19, 2007 / Notices
Fax written comments on the
collection of information by December
19, 2007.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–6974, or e-mailed to
baguilar@omb.eop.gov. All comments
should be identified with the OMB
control number 0910–NEW and title
‘‘Draft Guidance for Industry:
Cooperative Manufacturing
Arrangements for Licensed Biologics.’’
Also include the FDA docket number
found in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT:
Jonna Capezzuto, Office of the Chief
Information Officer (HFA–250), Food
and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, 301–827–
4659.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
DATES:
rwilkins on PROD1PC63 with NOTICES
Draft Guidance for Industry:
Cooperative Manufacturing
Arrangements for Licensed Biologics—
(OMB Control Number 0910–NEW)
The draft guidance document, when
finalized, will provide information
concerning cooperative manufacturing
arrangements applicable to biological
products subject to licensure under
section 351 of the U.S. Public Health
Service Act. The draft guidance
addresses several types of
manufacturing arrangements (i.e., short
supply arrangements, divided
manufacturing arrangements, shared
manufacturing arrangements, and
contract manufacturing arrangements)
and describes certain reporting and
recordkeeping responsibilities,
associated with these arrangements, for
the licensed manufacturer(s), contract
manufacturer(s), and final product
manufacturer(s) including the following:
(1) Notification of any proposed change
in the product, production process,
quality controls or facilities; (2)
notification of results of tests and
investigations related to or impacting
the product; (3) notification of products
manufactured in a contract facility; and
(4) standard operating procedures.
A. Notification of Any Proposed Change
in the Product, Production Process,
Quality Controls or Facility
Each licensed manufacturer in a
divided manufacturing arrangement or
VerDate Aug<31>2005
20:17 Nov 16, 2007
Jkt 214001
shared manufacturing arrangement must
notify the appropriate FDA Center
regarding proposed changes in the
manufacture, testing, or specifications of
its product, in accordance with § 601.12
(21 CFR 601.12). In the draft guidance,
we recommend that each licensed
manufacturer that proposes such a
change should inform other
participating licensed manufacturer(s)
of the proposed change.
For contract manufacturing
arrangements, we recommend that the
contract manufacturer should share
with the license manufacturer all
important proposed changes to
production and facilities (including
introduction of new products or at
inspection). The license holder is
responsible for reporting these changes
to FDA (§ 601.12).
B. Notification of Results of Tests and
Investigations Related to or Impacting
the Product
In the draft guidance, we recommend
the following for contract manufacturing
arrangements:
• The contract manufacturer should
fully inform the license manufacturer of
the results of all tests and investigations
regarding or possibly having an impact
on the product; and
• The license manufacturer should
obtain assurance from the contractor
that any FDA list of inspectional
observations will be shared with the
license manufacturer to allow
evaluation of its impact on the purity,
potency, and safety of the license
manufacturer’s product.
C. Notification of Products
Manufactured in a Contract Facility
In the draft guidance, we recommend
for contract manufacturing
arrangements that a license
manufacturer cross reference a contract
manufacturing facility’s Master Files
only in circumstances involving certain
proprietary information of the contract
manufacturer such as a list of all
products manufactured in a contract
facility. In this situation the license
manufacturer should be kept informed
of the types or categories of all products
manufactured in the contract facility.
D. Standard Operating Procedures
In the draft guidance, we remind the
license manufacture that the license
manufacturer assumes responsibility for
compliance with the applicable product
and establishment standards (§ 600.3(t))
(21 CFR 600.3(t)). Therefore, if the
license manufacturer enters into an
agreement with a contract
manufacturing facility, the license
manufacturer must ensure that the
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
65035
facility complies with the applicable
standards. An agreement between a
license manufacturer and a contract
manufacturing facility normally
includes procedures to regularly assess
the contract manufacturing facility’s
compliance. These procedures may
include, but are not limited to, review
of records and manufacturing deviations
and defects, and periodic audits.
For shared manufacturing
arrangements, each manufacturer must
submit a separate biologics license
application describing the
manufacturing facilities and operations
applicable to the preparation of that
manufacturer’s biological substance or
product (§ 601.2(a)) (21 CFR 601.2(a)). In
this draft guidance, we expect the
manufacturer that prepares (or is
responsible for the preparation of) the
product in final form for commercial
distribution to assume primary
responsibility for providing data
demonstrating the safety, purity, and
potency of the final product. We also
expect the licensed finished product
manufacturer to be primarily
responsible for any postapproval
obligations, such as postmarketing
clinical trials, additional product
stability studies, complaint handling,
recalls, postmarket reporting of the
dissemination of advertising and
promotional labeling materials as
required under § 601.12(f)(4) and
adverse experience reporting. We
recommend that the final product
manufacturer establish a procedure with
the other participating manufacturer(s)
to obtain information in these areas.
Description of Respondents: The
recordkeeping and reporting
recommendations described in this
document affect the participating
licensed manufacturer(s), final product
manufacturer(s), and contract
manufacturer(s) associated with
cooperative manufacturing
arrangements.
Burden Estimate: We believe that the
information collection provisions in the
draft guidance do not create a new
burden for respondents. We believe the
reporting and recordkeeping provisions
are part of usual and customary
business practice. Licensed
manufacturers would have contractual
agreements with participating licensed
manufacturers, final product
manufacturers, and contract
manufacturers, as applicable for the
type of cooperative manufacturing
arrangement, to address all these
information collection provisions.
This draft guidance also refers to
previously approved collections of
information found in FDA regulations at
parts 201, 207, 211, 600, 601, 606, 607,
E:\FR\FM\19NON1.SGM
19NON1
65036
Federal Register / Vol. 72, No. 222 / Monday, November 19, 2007 / Notices
610, 660, 803, and 807 (21 CFR parts
201, 207, 211, 600, 601, 606, 607, 610,
660, 803, and 807). The collections of
information in §§ 606.121, 606.122, and
610.40 have been approved under OMB
Control No. 0910–0116; § 610.2 has been
approved under OMB Control No. 0910–
0206; §§ 600.12(e) and 600.80 have been
approved under OMB Control No. 0910–
0308; §§ 601.2(a), 601.12, 610.60,
610.61, 610.62, 610.67, 660.2(c),
660.28(a) and (b), 660.35(a), (c) through
(g), and (i) through (m), 660.45, and
660.55(a) and (b) have been approved
under OMB Control No. 0910–0338;
§§ 803.20, 803.50, and 803.53 have been
approved under OMB Control No. 0910–
0437; and §§ 600.14 and 606.171 have
been approved under OMB Control No.
0910–0458. The current good
manufacturing practice regulations for
finished pharmaceuticals (part 211)
have been approved under OMB Control
No. 0910–0139; the establishment
registration regulations (parts 207, 607,
and 807) have been approved under
OMB Control Nos. 0910–0045, 0910–
0052, and 0910–0387; and the labeling
regulations (part 201) have been
approved under OMB Control Nos.
0910–0340 and 0910–0370.
In the Federal Register of July 23,
2007 (72 FR 40157), FDA published a
60-day notice requesting public
comment on the information collection
provisions. No comments were received
on the information collection.
Dated: November 13, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E7–22489 Filed 11–16–07; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2007N–0325]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Medical Devices:
Recommended Glossary and
Educational Outreach to Support Use
of Symbols on Labels and in Labeling
of In Vitro Diagnostic Devices Intended
for Professional Use
AGENCY:
Food and Drug Administration,
rwilkins on PROD1PC63 with NOTICES
HHS.
VerDate Aug<31>2005
20:17 Nov 16, 2007
Jkt 214001
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by December
19, 2007.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–6974, or e-mailed to
baguilar@omb.eop.gov. All comments
should be identified with the OMB
control number 0910–0553. Also
include the FDA docket number found
in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT:
Denver Presley, Jr., Office of Chief
Information Officer (HFA–250), Food
and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, 301–827–
1472.
In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
SUPPLEMENTARY INFORMATION:
Medical Devices: Recommended
Glossary and Educational Outreach to
Support Use of Symbols on Labels and
in Labeling of In Vitro Diagnostic
Devices Intended for Professional Use—
Section 502 of the Federal Food, Drug,
and Cosmetic Act/Section 351 of the
Public Health Service Act (OMB
Control Number 0910–0553)—Extension
Section 502 of the Federal Food, Drug,
and Cosmetic Act (FFD&C Act) (21
U.S.C. 352), among other things,
establishes requirements for the label or
labeling of a medical device so that it is
not misbranded. Section 351 of the
Public Health Service Act (the PHS Act)
(42 U.S.C. 262), establishes
requirements that manufacturers of
biological products must submit a
license application for FDA review and
approval prior to marketing a biological
product for introduction into interstate
commerce.
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
In the Federal Register of November
30, 2004, FDA published a notice of
availability of the final guidance
entitled ‘‘Use of Symbols on Labels and
in Labeling of In Vitro Diagnostic
Devices Intended for Professional Use.’’
The guidance document provides
guidance for the voluntary use of
selected symbols in place of text in
labeling. It provides the labeling
guidance required for: (1) In vitro
diagnostic devices (IVDs), intended for
professional use under 21 CFR 809.10,
FDA’s labeling requirements for IVDs,
and (2) FDA’s labeling requirements for
biologics, including IVDs under 21 CFR
parts 610 and 660. Under section 502(c)
of the FFD&C Act, a drug or device is
misbranded, ‘‘If any word, statement, or
other information required by or under
authority of this Act to appear on the
label or labeling is not prominently
placed thereon with such
conspicuousness (as compared with
other words, statements, designs, or
devices, in the labeling) and in such
terms as to render it likely to be read
and understood by the ordinary
individual under customary conditions
of purchase and use.’’ The guidance
document recommends that a glossary
of terms accompany each IVD to define
the symbols used on that device’s labels
and/or labeling. Furthermore, the
guidance recommends an educational
outreach effort to enhance the
understanding of newly introduced
symbols. Both the glossary and
educational outreach information will
help to ensure that IVD users will have
enough general familiarity with the
symbols used, as well as provide a quick
reference for available materials, thereby
further ensuring that such labeling
satisfies the labeling requirements under
section 502(c) of the FFD&C Act and
section 351 of the PHS Act.
In the Federal Register of August 31,
2007 (72 FR 50373), FDA published a
60-day notice soliciting public comment
on the proposed collection of
information provisions. No comments
were received.
The likely respondents for this
collection of information are IVD
manufacturers who plan to use the
selected symbols in place of text on the
labels and/or labeling of their IVDs.
FDA estimates the burden for this
collection of information as follows:
E:\FR\FM\19NON1.SGM
19NON1
]]>Agencies
[Federal Register Volume 72, Number 222 (Monday, November 19, 2007)]
[Notices]
[Pages 65034-65036]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-22489]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 1999D-2013]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Draft Guidance for
Industry: Cooperative Manufacturing Arrangements for Licensed Biologics
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
[[Page 65035]]
DATES: Fax written comments on the collection of information by
December 19, 2007.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-6974, or e-mailed to baguilar@omb.eop.gov. All comments
should be identified with the OMB control number 0910-NEW and title
``Draft Guidance for Industry: Cooperative Manufacturing Arrangements
for Licensed Biologics.'' Also include the FDA docket number found in
brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Jonna Capezzuto, Office of the Chief
Information Officer (HFA-250), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, 301-827-4659.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Draft Guidance for Industry: Cooperative Manufacturing Arrangements for
Licensed Biologics--(OMB Control Number 0910-NEW)
The draft guidance document, when finalized, will provide
information concerning cooperative manufacturing arrangements
applicable to biological products subject to licensure under section
351 of the U.S. Public Health Service Act. The draft guidance addresses
several types of manufacturing arrangements (i.e., short supply
arrangements, divided manufacturing arrangements, shared manufacturing
arrangements, and contract manufacturing arrangements) and describes
certain reporting and recordkeeping responsibilities, associated with
these arrangements, for the licensed manufacturer(s), contract
manufacturer(s), and final product manufacturer(s) including the
following: (1) Notification of any proposed change in the product,
production process, quality controls or facilities; (2) notification of
results of tests and investigations related to or impacting the
product; (3) notification of products manufactured in a contract
facility; and (4) standard operating procedures.
A. Notification of Any Proposed Change in the Product, Production
Process, Quality Controls or Facility
Each licensed manufacturer in a divided manufacturing arrangement
or shared manufacturing arrangement must notify the appropriate FDA
Center regarding proposed changes in the manufacture, testing, or
specifications of its product, in accordance with Sec. 601.12 (21 CFR
601.12). In the draft guidance, we recommend that each licensed
manufacturer that proposes such a change should inform other
participating licensed manufacturer(s) of the proposed change.
For contract manufacturing arrangements, we recommend that the
contract manufacturer should share with the license manufacturer all
important proposed changes to production and facilities (including
introduction of new products or at inspection). The license holder is
responsible for reporting these changes to FDA (Sec. 601.12).
B. Notification of Results of Tests and Investigations Related to or
Impacting the Product
In the draft guidance, we recommend the following for contract
manufacturing arrangements:
The contract manufacturer should fully inform the license
manufacturer of the results of all tests and investigations regarding
or possibly having an impact on the product; and
The license manufacturer should obtain assurance from the
contractor that any FDA list of inspectional observations will be
shared with the license manufacturer to allow evaluation of its impact
on the purity, potency, and safety of the license manufacturer's
product.
C. Notification of Products Manufactured in a Contract Facility
In the draft guidance, we recommend for contract manufacturing
arrangements that a license manufacturer cross reference a contract
manufacturing facility's Master Files only in circumstances involving
certain proprietary information of the contract manufacturer such as a
list of all products manufactured in a contract facility. In this
situation the license manufacturer should be kept informed of the types
or categories of all products manufactured in the contract facility.
D. Standard Operating Procedures
In the draft guidance, we remind the license manufacture that the
license manufacturer assumes responsibility for compliance with the
applicable product and establishment standards (Sec. 600.3(t)) (21 CFR
600.3(t)). Therefore, if the license manufacturer enters into an
agreement with a contract manufacturing facility, the license
manufacturer must ensure that the facility complies with the applicable
standards. An agreement between a license manufacturer and a contract
manufacturing facility normally includes procedures to regularly assess
the contract manufacturing facility's compliance. These procedures may
include, but are not limited to, review of records and manufacturing
deviations and defects, and periodic audits.
For shared manufacturing arrangements, each manufacturer must
submit a separate biologics license application describing the
manufacturing facilities and operations applicable to the preparation
of that manufacturer's biological substance or product (Sec. 601.2(a))
(21 CFR 601.2(a)). In this draft guidance, we expect the manufacturer
that prepares (or is responsible for the preparation of) the product in
final form for commercial distribution to assume primary responsibility
for providing data demonstrating the safety, purity, and potency of the
final product. We also expect the licensed finished product
manufacturer to be primarily responsible for any postapproval
obligations, such as postmarketing clinical trials, additional product
stability studies, complaint handling, recalls, postmarket reporting of
the dissemination of advertising and promotional labeling materials as
required under Sec. 601.12(f)(4) and adverse experience reporting. We
recommend that the final product manufacturer establish a procedure
with the other participating manufacturer(s) to obtain information in
these areas.
Description of Respondents: The recordkeeping and reporting
recommendations described in this document affect the participating
licensed manufacturer(s), final product manufacturer(s), and contract
manufacturer(s) associated with cooperative manufacturing arrangements.
Burden Estimate: We believe that the information collection
provisions in the draft guidance do not create a new burden for
respondents. We believe the reporting and recordkeeping provisions are
part of usual and customary business practice. Licensed manufacturers
would have contractual agreements with participating licensed
manufacturers, final product manufacturers, and contract manufacturers,
as applicable for the type of cooperative manufacturing arrangement, to
address all these information collection provisions.
This draft guidance also refers to previously approved collections
of information found in FDA regulations at parts 201, 207, 211, 600,
601, 606, 607,
[[Page 65036]]
610, 660, 803, and 807 (21 CFR parts 201, 207, 211, 600, 601, 606, 607,
610, 660, 803, and 807). The collections of information in Sec. Sec.
606.121, 606.122, and 610.40 have been approved under OMB Control No.
0910-0116; Sec. 610.2 has been approved under OMB Control No. 0910-
0206; Sec. Sec. 600.12(e) and 600.80 have been approved under OMB
Control No. 0910-0308; Sec. Sec. 601.2(a), 601.12, 610.60, 610.61,
610.62, 610.67, 660.2(c), 660.28(a) and (b), 660.35(a), (c) through
(g), and (i) through (m), 660.45, and 660.55(a) and (b) have been
approved under OMB Control No. 0910-0338; Sec. Sec. 803.20, 803.50,
and 803.53 have been approved under OMB Control No. 0910-0437; and
Sec. Sec. 600.14 and 606.171 have been approved under OMB Control No.
0910-0458. The current good manufacturing practice regulations for
finished pharmaceuticals (part 211) have been approved under OMB
Control No. 0910-0139; the establishment registration regulations
(parts 207, 607, and 807) have been approved under OMB Control Nos.
0910-0045, 0910-0052, and 0910-0387; and the labeling regulations (part
201) have been approved under OMB Control Nos. 0910-0340 and 0910-0370.
In the Federal Register of July 23, 2007 (72 FR 40157), FDA
published a 60-day notice requesting public comment on the information
collection provisions. No comments were received on the information
collection.
Dated: November 13, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E7-22489 Filed 11-16-07; 8:45 am]
BILLING CODE 4160-01-S
